Long-Term Debt: Verastem Inc (VSTM)

Brandmark of Verastem Corp (VSTM)

The business of Verastem, Inc. (VSTM) relies on the success of trials for agents against solid tumors and regulatory support. The price action, reaching 0.11, links operational achievements to a partnership strategy with global laboratories to develop RAS inhibitors. However, uncertainty regarding the final trial phases of avutometinib and the need for new equity offerings due to liquidity shortages create significant financial threats.

VSTM (Verastem Inc) Company Long-Term Debt history from 07/04/2022 to 10/29/2026

Verastem Inc - analytical breakdowns and key metrics (VSTM)

- current quotes and average value forecast:
Stock Quotes verastem.com|VSTM - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Verastem|VSTM - Total Company Value
- book capitalization data:
Net Assets per Single Share Verastem|VSTM - Company Book Value|Market-to-Book Ratio verastem.com|VSTM - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Verastem, Inc.|VSTM - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Verastem Corp|VSTM - Company Total Debt|Debt to Net Assets Ratio Verastem|VSTM - Company Long-Term Liabilities|Amount of Current Liabilities Verastem|Quick Ratio verastem.com
- net income and valuation multiples indicators:
VSTM - Company Net Income
Fundamental company valuation:verastem.com
Core merchandise of Verastem

This indicator aggregates all financial obligations with maturities exceeding twelve months, measuring the issuer's long-term debt load and overall solvency. For Verastem, Inc. (VSTM), borrowings fund costly oncology research until the company secures monopoly pricing power; therefore, the company's long-term debt trajectory serves as an indicator of its financial runway before its drugs enter the market.

Competitor analysis for Verastem, Inc.

GMAB - Company Long-Term Liabilities|EXEL - Company Long-Term Debt|Long-Term Debt Nuvalent Inc|Kymera Therapeutics Inc (KYMR) - Company Long-Term Debt|IDYA (IDEAYA Corp) - Company Long-Term Debt|Company Long-Term Debt Enliven Therapeutics|Long-Term Debt oricpharma.com ORIC|Company Long-Term Debts RLAY|Nurix Therapeutics Inc (NRIX) - Long-Term Indebtedness|Tyra Bio - Company Long-Term Liabilities|Monte Rosa Corp (GLUE) - Long-Term Debt|CGEM: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IMRX (immuneering.com)|CCCC (C4 Therapeutics) - Company Long-Term Liabilities|BDTX: Amount of Long-Term Liabilities|RPTX (Repare Rx) - Company Long-Term Debts|Company Long-Term Debts PMV Pharmaceuticals, Inc|Company Long-Term Debt Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts BGMS (Bio Green Med Solution)|Long-Term Indebtedness Aadi Bioscience Inc|Aileron - Company Long-Term Debts|Long-Term Debt Blueprint Medicines|GLYC (glycomimetics.com) - Company Long-Term Liabilities|SWTX: Amount of Long-Term Liabilities